2022
Concurrent use of tumor necrosis factor inhibitor and tyrosine kinase inhibitor in ankylosing spondylitis and myeloid neoplasm
Gupta A, Department of Medicine Y, Afinogenova Y, Podoltsev N, Danve A, Section of Rheumatology A, Section of Hematology D. Concurrent use of tumor necrosis factor inhibitor and tyrosine kinase inhibitor in ankylosing spondylitis and myeloid neoplasm. European Journal Of Rheumatology 2022, 9: 215-216. PMID: 35156633, DOI: 10.5152/eurjrheum.2022.21097.Peer-Reviewed Case Reports and Technical NotesMyeloid neoplasmsBiologic disease-modifying agentsTumor necrosis factor inhibitorsTyrosine kinase inhibitor imatinibNecrosis factor inhibitorsAutoimmune rheumatic diseasesDisease-modifying agentsKinase inhibitor imatinibTyrosine kinase inhibitorsMiddle-aged malesRheumatic diseasesFactor inhibitorsPatients' qualityFavorable outcomeHematologic malignanciesInhibitor imatinibBeta rearrangementInfliximabConcurrent useKinase inhibitorsCancer diagnosisPatientsNeoplasmsAppropriate casesInhibitors
2019
Autoimmune myositis and myasthenia gravis resulting from a combination therapy with nivolumab and ipilimumab for metastatic melanoma
Department of Internal Medicine Y, Sutaria R, Patel P, Department of Rheumatology Y, Danve A. Autoimmune myositis and myasthenia gravis resulting from a combination therapy with nivolumab and ipilimumab for metastatic melanoma. European Journal Of Rheumatology 2019, 6: 153-154. PMID: 30986169, PMCID: PMC6668642, DOI: 10.5152/eurjrheum.2019.18159.Peer-Reviewed Original ResearchMetastatic melanomaCheckpoint inhibitorsMyasthenia gravisAutoimmune myositisCombination of ipilimumabCytotoxic T lymphocytesCombination therapyT lymphocytesImmune responseAdverse effectsMelanomaNumerous immuneIpilimumabNivolumabNovel optionGravisMyositisDeactivation signalsInhibitorsMalignancyTherapyTumors
2017
Do Tumor Necrosis Factor (TNF) Inhibitors Improve the Glycemic Control in Patients with Rheumatoid Arthritis and Concomitant Diabetes Mellitus?
Danve AS, Kulkarni S. Do Tumor Necrosis Factor (TNF) Inhibitors Improve the Glycemic Control in Patients with Rheumatoid Arthritis and Concomitant Diabetes Mellitus? American Journal Of Therapeutics 2017, 24: e347-e350. PMID: 26103543, DOI: 10.1097/mjt.0000000000000297.Peer-Reviewed Original ResearchConceptsRheumatoid arthritisGlycemic controlTNF inhibitorsInsulin resistanceInsulin sensitivityTumor necrosis factor inhibitorsTumor necrosis factor alphaConcomitant rheumatoid arthritisInflammatory rheumatic diseasesNecrosis factor inhibitorsNecrosis factor alphaIncident diabetesDiabetes mellitusRheumatic diseasesFactor inhibitorsProinflammatory cytokinesFactor alphaPatientsMellitusArthritisInhibitorsDiabetesInflammationCytokinesDisease